Benzinga | Nov 5, 2020 07:11AM EST

Kala Pharmaceuticals Q3 EPS $(0.50) Misses $(0.44) Estimate, Sales $2.22M Beat $2.01M Estimate

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 26.47 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $2.22 million which beat the analyst consensus estimate of $2.01 million by 10.45 percent. This is a 53.00 percent increase over sales of $1.45 million the same period last year.